Global Factor IX Deficiency Treatment Market 2017-2021

第Ⅸ因子欠乏症治療の世界市場2017-2021

◆タイトル:Global Factor IX Deficiency Treatment Market 2017-2021
◆商品コード:IRTNTR12153
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年3月7日
◆ページ数:70
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥486,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、第Ⅸ因子欠乏症治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、第Ⅸ因子欠乏症治療の世界市場規模及び予測、種類別分析、市場シェア、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・第Ⅸ因子欠乏症治療の世界市場:市場概観
・第Ⅸ因子欠乏症治療の世界市場:業界の構造分析
・第Ⅸ因子欠乏症治療の世界市場:疾患概要
・第Ⅸ因子欠乏症治療の世界市場:市場規模及び予測
・第Ⅸ因子欠乏症治療の世界市場:種類別分析
・第Ⅸ因子欠乏症治療の世界市場:地域別分析
・第Ⅸ因子欠乏症治療の世界市場:アジア市場規模
・第Ⅸ因子欠乏症治療の世界市場:アメリカ市場規模
・第Ⅸ因子欠乏症治療の世界市場:ヨーロッパ市場規模
・第Ⅸ因子欠乏症治療の世界市場:成長要因
・第Ⅸ因子欠乏症治療の世界市場:課題
・第Ⅸ因子欠乏症治療の世界市場:市場シェア
・第Ⅸ因子欠乏症治療の世界市場:購買基準
・第Ⅸ因子欠乏症治療の世界市場:製品パイプライン分析
・第Ⅸ因子欠乏症治療の世界市場:市場動向
・第Ⅸ因子欠乏症治療の世界市場:競争状況
・第Ⅸ因子欠乏症治療の世界市場:主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

ABSTRACTAbout Factor IX Deficiency Treatment

The global factor IX deficiency treatment market is characterized by the presence of various therapeutic products provided by some of the top vendors such as Shire, CSL Behring, Novo Nordisk, Biogen, and Pfizer. The adoption rate of therapeutics has undergone a paradigm shift toward the introduction of gene therapy, which will lead to the development of new products. However, the low penetration rate of recombinant therapy in developing countries is the current challenge in the market. This low penetration rate in developing countries is due to the higher cost of recombinant drugs, limited disease knowledge, and a shortage of treatment supplies. Nevertheless, the market has observed a positive side of individuals adopting recombinant drugs is expected to improve the diagnosis and treatment rates for hemophilia B in the medium- to long-term.

Technavio’s analysts forecast the global factor IX deficiency treatment market to grow at a CAGR of 5.12% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global factor IX deficiency treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of factor IX products in the different diseases.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Factor IX Deficiency Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Biogen
• CSL Behring
• Novo Nordisk
• Pfizer
• Shire

[Market driver]
• Growing pipeline with increased focus to meet unmet demand.
• For a full, detailed list, view our report

[Market challenge]
• Emerging price war in the industry.
• For a full, detailed list, view our report

[Market trend]
• Increase in investments in the production and discovery.
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Highlights

PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by disease type
• Global hemophilia B drugs market
• Global hemophilia B inhibitors market

PART 09: Market segmentation by type of therapy
• Recombinant therapies
• Plasma-derived therapies

PART 10: Market segmentation by type of disease management
• Prophylaxis
• On-demand therapy
• Inhibitor therapy

PART 11: Geographical segmentation
• Factor IX drugs market in Americas
• Factor IX drugs market in EMEA
• Factor IX drugs market in APAC

PART 12: Market drivers
• Shifting toward half-life drugs
• Special designations promote novel launches
• Growing pipeline with increased focus to meet unmet demand

PART 13: Impact of drivers

PART 14: Market challenges
• Emerging price war in the industry
• Low penetration rate
• Lack of complete remission
• High entry barriers

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Increasing focus on gene therapy
• Increase in investments in the production and discovery
• Strategic initiatives should lead to consolidation

PART 17: Vendor landscape
• Competitive scenario

PART 18: Key vendor analysis
• Biogen
• CSL Behring
• Novo Nordisk
• Pfizer
• Shire

PART 19: Appendix
• List of abbreviations

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Process of gene therapy
Exhibit 03: Key buying criteria and customer segments of global factor IX deficiency treatment market
Exhibit 04: Key customer segments of factor IX deficiency treatment market
Exhibit 05: Pipeline analysis
Exhibit 06: Key clinical trials
Exhibit 07: Global factor IX deficiency treatment market snapshot
Exhibit 08: Global factor IX deficiency treatment market by revenue 2016-2021 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Hemophilia B drugs market for global factor IX deficiency treatment market 2016-2021 ($ millions)
Exhibit 11: Hemophilia B inhibitors market for global factor IX deficiency treatment market 2016-2021 ($ millions)
Exhibit 12: Global factor IX recombinant therapies market 2016-2021 ($ millions)
Exhibit 13: Global factor IX plasma-derived therapies market 2016-2021 ($ millions)
Exhibit 14: Segmentation of factor IX drugs market by type of disease management 2016
Exhibit 15: Factor IX deficiency treatment market in Americas 2016-2021 ($ millions)
Exhibit 16: Factor IX deficiency treatment market in EMEA 2016-2021 ($ millions)
Exhibit 17: Factor IX deficiency treatment market in APAC 2016-2021($ millions)
Exhibit 18: Launch of half-life drugs for treatment of factor IX deficiency
Exhibit 19: Special designation to factor IX drugs in 2016
Exhibit 20: A few late-stage (Phase III) factor IX drugs
Exhibit 21: Impact of drivers
Exhibit 22: Impact of drivers and challenges
Exhibit 23: Competitive structure of global factor IX deficiency treatment market 2016
Exhibit 24: Competitive analysis of global factor IX deficiency treatment market
Exhibit 25: Market share analysis 2016
Exhibit 26: Market penetration of factor IX vendors 2016
Exhibit 27: Biogen: Key highlights
Exhibit 28: Biogen: Strength assessment
Exhibit 29: Biogen: Strategy assessment
Exhibit 30: Biogen: Opportunity assessment
Exhibit 31: Year-over-year (YoY) revenue of ALPROLIX 2014-2016 ($ millions)
Exhibit 32: CSL Behring: Key highlights
Exhibit 33: CSL Behring: Strength assessment
Exhibit 34: CSL Behring: Strategy assessment
Exhibit 35: CSL Behring: Opportunity assessment
Exhibit 36: Novo Nordisk: Key highlights
Exhibit 37: Novo Nordisk: Strength assessment
Exhibit 38: Novo Nordisk: Strategy assessment
Exhibit 39: Novo Nordisk: Opportunity assessment
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment
Exhibit 44: Shire: Key highlights
Exhibit 45: Shire: Strength assessment
Exhibit 46: Shire: Strategy assessment
Exhibit 47: Shire: Opportunity assessment
Exhibit 48: Shire: YoY revenue comparison of RIXUBIS 2014 and 2015 ($ millions)



【掲載企業】

Biogen, CSL Behring, Novo Nordisk, Pfizer, and Shire.

【資料のキーワード】

第Ⅸ因子欠乏症、第Ⅸ因子欠乏症治療薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[第Ⅸ因子欠乏症治療の世界市場2017-2021]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆